Article Versions Notes

Wu T-C, Lin P-T, Teng W, Shen EY-L, Su C-W, Hsieh Y-C, Chen W-T, Wu T-H, Lin C-C, Lin S-M, et al. Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab. Cancers. 2025; 17(19):3157. https://doi.org/10.3390/cancers17193157

Wu, Tai-Chi, Po-Ting Lin, Wei Teng, Eric Yi-Liang Shen, Chung-Wei Su, Yi-Chung Hsieh, Wei-Ting Chen, Tsung-Han Wu, Chen-Chun Lin, Shi-Ming Lin, and et al. 2025. "Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab" Cancers 17, no. 19: 3157. https://doi.org/10.3390/cancers17193157

Wu, T.-C., Lin, P.-T., Teng, W., Shen, E. Y.-L., Su, C.-W., Hsieh, Y.-C., Chen, W.-T., Wu, T.-H., Lin, C.-C., Lin, S.-M., & Lin, C.-Y. (2025). Moderate Immune-Related Liver Injury Is a Good Factor in Patients with Hepatoma Under Atezolizumab Plus Bevacizumab. Cancers, 17(19), 3157. https://doi.org/10.3390/cancers17193157